These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24034607)

  • 1. Finding a sugary foothold: how antibiotics pave the way for enteric pathogens.
    Stecher B
    Cell Host Microbe; 2013 Sep; 14(3):225-7. PubMed ID: 24034607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An antibiotic-altered microbiota provides fuel for the enteric foe.
    Stiemsma LT; Turvey SE; Finlay BB
    Cell Res; 2014 Jan; 24(1):5-6. PubMed ID: 24165893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How enteric pathogens know they hit the sweet spot.
    Alvarado I; Abel-Santos E
    Future Microbiol; 2014; 9(1):13-6. PubMed ID: 24328376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens.
    Ng KM; Ferreyra JA; Higginbottom SK; Lynch JB; Kashyap PC; Gopinath S; Naidu N; Choudhury B; Weimer BC; Monack DM; Sonnenburg JL
    Nature; 2013 Oct; 502(7469):96-9. PubMed ID: 23995682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of bacterial metabolism and physiology in the pathogenesis of Clostridium difficile disease.
    Bongaerts GP; Lyerly DM
    Microb Pathog; 1997 Apr; 22(4):253-6. PubMed ID: 9140922
    [No Abstract]   [Full Text] [Related]  

  • 6. [Antibiotic-associated diarrhea].
    Reisinger EC; Lademann M; Krause R
    Dtsch Med Wochenschr; 2004 Sep; 129 Suppl 2():S111-3. PubMed ID: 15368187
    [No Abstract]   [Full Text] [Related]  

  • 7. Intestinal alkaline phosphatase prevents antibiotic-induced susceptibility to enteric pathogens.
    Alam SN; Yammine H; Moaven O; Ahmed R; Moss AK; Biswas B; Muhammad N; Biswas R; Raychowdhury A; Kaliannan K; Ghosh S; Ray M; Hamarneh SR; Barua S; Malo NS; Bhan AK; Malo MS; Hodin RA
    Ann Surg; 2014 Apr; 259(4):715-22. PubMed ID: 23598380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal microbiota transplant for C. difficile infection: Just say yes.
    Cammarota G; Gallo A; Bibbò S
    Anaerobe; 2019 Dec; 60():102109. PubMed ID: 31644957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection.
    Naaber P; Mikelsaar RH; Salminen S; Mikelsaar M
    J Med Microbiol; 1998 Jul; 47(7):591-8. PubMed ID: 9839563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host-mediated sugar oxidation promotes post-antibiotic pathogen expansion.
    Faber F; Tran L; Byndloss MX; Lopez CA; Velazquez EM; Kerrinnes T; Nuccio SP; Wangdi T; Fiehn O; Tsolis RM; Bäumler AJ
    Nature; 2016 Jun; 534(7609):697-9. PubMed ID: 27309805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clostridium difficile colitis: pathogenesis and host defence.
    Abt MC; McKenney PT; Pamer EG
    Nat Rev Microbiol; 2016 Oct; 14(10):609-20. PubMed ID: 27573580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection.
    Ross CL; Spinler JK; Savidge TC
    Anaerobe; 2016 Oct; 41():37-43. PubMed ID: 27180006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of candidemia in patients with Clostridium difficile infection.
    Falcone M; Venditti M; Sanguinetti M; Posteraro B
    Expert Rev Anti Infect Ther; 2016 Jul; 14(7):679-85. PubMed ID: 27254270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.
    Andersson JA; Fitts EC; Kirtley ML; Ponnusamy D; Peniche AG; Dann SM; Motin VL; Chauhan S; Rosenzweig JA; Sha J; Chopra AK
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3717-29. PubMed ID: 27067323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Working out the bug in the accordion.
    Chandok N; Kamath PS
    Gastroenterology; 2009 Jul; 137(1):e5-6. PubMed ID: 19501204
    [No Abstract]   [Full Text] [Related]  

  • 16. Basic and clinical aspects of Clostridium difficile colitis.
    Morishita T; Nakayama T; Kamiya T; Mori S; Isobe K; Furuta Y
    Rev Gastroenterol Peru; 2004; 24(3):263-9. PubMed ID: 15483687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract.
    Winston JA; Theriot CM
    Anaerobe; 2016 Oct; 41():44-50. PubMed ID: 27163871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile.
    Engevik MA; Engevik KA; Yacyshyn MB; Wang J; Hassett DJ; Darien B; Yacyshyn BR; Worrell RT
    Am J Physiol Gastrointest Liver Physiol; 2015 Mar; 308(6):G497-509. PubMed ID: 25552580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotics and Clostridium difficile.
    Freeman J; Wilcox MH
    Microbes Infect; 1999 Apr; 1(5):377-84. PubMed ID: 10602670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal microbiota transplantation in the treatment of Clostridium difficile infections.
    Austin M; Mellow M; Tierney WM
    Am J Med; 2014 Jun; 127(6):479-83. PubMed ID: 24582877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.